TGFB1 and colorectal carcinoma: However, recurrence after chemotherapy is the barrier to effective clinical outcomes for CRC patients; we reported that, as a mechanism of resistance, 5-FU activates the TGFB pathway [32], and that targeting TGFBRI restored the sensitivity of drug-resistant cells to 5-FU toxicity [33].